
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
In a Federal Register notice, the Food & Drug Administration is seeking comments regarding prescription drug authentication
The Food & Drug Administration is seeking comments at





